JPMorgan analyst Anupam Rama upgraded PTC Therapeutics (PTCT) to Overweight from Neutral citing an attractive risk/reward profile into the phase 3 results for Translarna in non-sense mutation Duchenne Muscular Dystrophy. The data are expected in Q4. Rama believes the study is designed for success and raised the firm's probability of success to 80%. PTC shares are off down 37% since the mid-March highs when takeout speculation was a key driver of appreciation, Rama tells investors this morning in a research note. The analyst raised PTC's price target to $100 from $74. Shares of PTC closed yesterday up $1.30 to $48.94.